Compare Skyworks Solutions Inc (SWKS) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Skyworks Solutions Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Skyworks Solutions Inc trades at $76.48 (market cap $12.15B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.66 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 4.8× Skyworks Solutions Inc's market cap, and Skyworks Solutions Inc pays the higher dividend (4.13%). Which is the better fit depends on your goals — on Pluang, investors hold Skyworks Solutions Inc for 50 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| SWKS | TAK | |
|---|---|---|
Market Cap | $12.15B | $58.74B |
Volume | 7,390,810 | 3,110,994 |
Sector | Technology | Health |
52-Week High | $91.45 | $19.05 |
52-Week Low | $52.50 | $13.23 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | $12.03B | $86.65B |
Dividend Yield | 4.13% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Skyworks Solutions (SWKS) trades at $83.43, up 0.88% on the day, with a neutral technical signal despite bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, though revenue and net income margins have declined year-over-year. The pending Qorvo merger, expected to close in 2026, represents a significant strategic move with $500 million in projected synergies, driving recent stock momentum and analyst optimism.
The investment case balances merger synergies and market expansion against declining profitability and integration risks. With 60% of analysts rating SWKS a Buy and a consensus price target of $78.80 (below current price), near-term upside appears limited. Key risks include execution of the Qorvo integration, competitive pressures in semiconductors, and macroeconomic headwinds affecting consumer electronics demand.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
